Quick Links
McGill.CA / Programme en génétique du cancer / La recherche / Les publications

Liste complète 2006-2007

Articles révisés par des pairs


2007

  1. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.Lancet Oncol. 8 (1): 26-34, 2007.



  2. Kotsopoulos J, Lubinski J, Lynch H.T, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C,Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E,Rennert G, Eng C, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 105(2):221-8, 2007.



  3. Refae MA, Wong N, Patenaude F, Bégin LR, Foulkes WD. Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma. Nature Clinical Practice Oncology. 4(4): 256-61, 2007.



  4. Hamel N, Wong N, Alpert L, Galvez M, Foulkes WD. Mixed ovarian germ cell tumor in a BRCA2 mutation carrier. Int J Gybecol Pathol. 26 (2):160-4, 2007.



  5. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, Van Beers EH, Li, L, Khalil T, Quenneville L, Omeroglu A, Poll A, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod S, Livingston DM, Foulkes WD. Analysis of PALB2/FANCN–associated breast cancer families. Proc Natl Acad Sci U S A. 104(16): 6788-93, 2007.



  6. Mesurolle B, Kadoch L,El-Khoury M, Lisbona A, Dendukuri N, Foulkes WD. Sonographic Features of Breast Carcinoma Presenting as Masses in BRCA Gene Mutation Carriers.Ultrasound Med. 26(6):817-24, 2007.



  7. Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L,Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Emanuelsson M, Isaacs WB. Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet. 1;16(11):1271-8, 2007.



  8. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 7(1):134, 2007.



  9. Apicella C, Dowty J, Dite G, Jenkins M, Senie R, Daly M, Andrulis I, John E, Buys S, Li F, Glendon G, Chung W, Ozcelik H, Miron A, Kotar K, Southey M, Foulkes WD, Hopper J. Validation study of the lambda model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clin Genet. 72(2):87-97, 2007.



  10. Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez PY, Al Moustafa AE. E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle. 6(16):2038-42, 2007.



  11. Foulkes WD. Clinically relevant biology of hereditary breast cancer. Semin Oncol. 34(5):379-83, 2007.



  12. Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E, Robidoux A, Martin G, Bismar TA, Tischkowitz M, Rousseau F, Narod SA. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res. 9(6):R83, 2007.



  13. Foulkes WD. P53-master and commander. N Engl J Med. 357(25):2539-41, 2007.
  14. Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene. 25;26(4):618-32, 2007.



  15. Benoît MH, Hudson TJ, Maire G, Squire JA, Arcand SL, Provencher D, Mes-Masson AM, Tonin PN. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines.Int J Oncol.30(1):5-17, 2007.



  16. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, Mes-Masson AM. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC).Mol Carcinog. 46(10):872-85, 2007.



  17. Ouellet V, Le Page C, Madore J, Guyot MC, Barrès V, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM. An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer. Cancer. 110(2):297-308, 2007.



  18. Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Fam Cancer. 6(4):491-7, 2007.



  19. Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia. 9(10):820-9, 2007.



  20. Wojnarowicz PM, Breznan A, Arcand SL, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN. Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. Int J Gynecol Cancer. 2007 Nov 19; [Epub ahead of print]



  21. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 39(2):162-4, 2007.



  22. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 92(8):3321-5, 2007.



  23. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 297(21):2360-72, 2007.



  24. Amrein L, Loignon M, Goulet AC, Dunn M, Jean-Claude B, Aloyz R, Panasci L. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. J Pharmacol Exp Ther. 321(3):848-55, 2007.



  25. Loignon M, Amrein L, Dunn M, Aloyz R. XRCC3 depletion induces spontaneous DNA breaks and p53-dependent cell death. Cell Cycle. 6(5):606-11, 2007.




2006

  1. Oros, KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin P. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Clin Genet. 70(4):320-329, 2006.



  2. Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S, Thibodeau SN, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Badzioch M, Bishop DT, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Guy M, Hsieh C-L, Halpern J, Balise RR, Oakley-Girvan I, Whittemore AS, Xu J, Dimitrov L, Chang B-L, Adams TS, Turner AR, Meyers DA, Friedrichsen DM, Deutsch K, Kolb S, Janer M, Hood L, Ostrander EA, Stanford JL, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Lange EM, Ho LA, Beebe-Dimmer JL, Wood DP, Cooney KA, Seminara D, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela T LJ, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson B-A, Grönberg H, Camp NJ, Farnham J, Cannon-Albright LA, Catalona WJ, Suarez BK, Roehl KA. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Human Genetics. 120(4):471-485, 2006.



  3. Tischkowitz M, Gologan A, Srolovitz H, Khanna M, Foulkes WD. Muir Torre syndrome and MSH2 mutations: the importance of dermatological awareness. Br J Cancer. 95 (2): 243-244.



  4. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with BRCA1 or BRCA2 mutation. JAMA. 296 (2): 185-192, 2006.



  5. Goswami RS, Minoo P, Baker K, Chong G, Foulkes WD, Jass JR. Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. Nat Clin Pract Oncol. 3 (5): 281-4, 2006.



  6. Galiatsatos P, Kasprzak L, Chong G, Jass JR, Foulkes WD. Multiple primary malignancies in a patient with situs ambiguous. Clin Genet 69 (6): 528-531, 2006.



  7. Foulkes WD. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis. Fam Cancer. 5 (2): 135-142, 2006.



  8. Soravia C, Delozier CD, Dobbie Z, Berthod CR, Arrigoni E, Brundler MA, Blouin JL, Foulkes WD, Hutter P. Double frameshift mutations in APC and MSH2 in the same individual. Int J Colorectal Dis. 21 (1): 79-83, 2006.



  9. Shinto E, Baker K, Tsuda H, Mochizuki H, Ueno H, Matsubara O, Foulkes WD , Jass JR. Tumor Buds Show Reduced Expression of Laminin-5 gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer. Dis. Colon and Rectum. 49(8):1193-1202, 2006.



  10. Baker K, Chong G, Foulkes WD , Jass JR. Transforming growth factor-pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology. 49(4):371-380, 2006.



  11. Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-Related Breast Cancer: Past, Present and Future. Cell Cycle. 5(9):963--7, 2006.



  12. Morel CF, Thomas MA, Cao H, O'Neil CH, Pickering JG, Foulkes WD, Hegele RA. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy (FPLD2). J Clin Endocrinol Metab. 91(7):2689-2695, 2006.



  13. Ouellet V, Guyot,M-C, Le Page,C, Filali-Mouhim A, Provencher D, Sanchez L, Tonin PN, Mes-Masson A-M. Tissue array validation of microarray candidates identifies new molecular markers that correlated with tumor grade and outcomes in serous epithelial ovarian cancer. Int J Cancer . 2006 Mar 29[Epub ahead of print]



  14. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study GRoup. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 8(2):R15, 2006.



  15. Li L, McVety S, Younan R, Du Sart D, Gordon PH, Hutter P, Hogervost FBL, Liang P, Chong G, Foulkes WD . Distinct patterns of Germ-Line Deletions in MLH1 and MLH2 : the Implication of Alu Repetitive Element in the genetic etiology of Lynch Syndrome (HNPCC). Hum Mutations. 27(4):388, 2006.



  16. Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domcheck S, Sun P; for the Hereditary Breast Cancer Clinical Study Group. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Lancet Oncol. 7(5): 402-6, 2006.



  17. Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson A-M, Foulkes WD, Ghadiran P, Provencher D, Tonin PN. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Medical Genetics 7:23, 2006.



  18. McVety S, Li L, Thiffault I, Gordon P.H, MacNamara E, Wong N, Australie K, Kasprzak L, Chong G, Foulkes WD . The value of multi-modal gene screening in HNPCC in Quebec: three mutations in mismatch repair genes that would have not been correctly identified by genomic DNA sequencing alone. Familial Cancer 5: 21-8, 2006.



  19. Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJ, Moller P, Apold J, Foulkes WD. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet. 2006 Mar 1;7(1):15 [Epub ahead of print]



  20. Gronwald J, Tung N, Foulkes WD , Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 118(9); 2281-4, 2006.



  21. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher D, Mes-Masson A-M. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer . 118:1750-8, 2006.



  22. Le Page C, Ouellet V, Madore J, Filali-Mouhim A, Ren F, Hudson T, Tonin PN, Provencher D, Mes-Masson A-M. Gene profiling in primary ovarian cultures highlights relevant markers of epithelial ovarian cancer. Br J Cancer. 94:436-445, 2006.



  23. Minoo P, Baker K, Goswami R, Chong G, Foulkes WD , Ruszkiewicz A, Barker M, Buchanan D, Young J, Jass JR. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut. 2006 Feb 9; [Epub ahead of print].



  24. Barker KT, Foulkes WD , Schwartz CE, Labadie C, Monsell F, Houlston RS, Harper J. Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? J Med Genet. 2006 Jan 27; [Epub ahead of print].



  25. Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes WD , Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer 118(1):103-7, 2006.



  26. Galiatsatos P, Foulkes WD . Familial adenomatous polyposis. Am J Gastroenterol 101(2): 385-98, 2006.



  27. McVety S, Li L, Gordon PH, Chong G, Foulkes WD . Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. J Med Genet 43(2): 153-6, 2006.





Livres et articles révisés ou non par des pairs


  1. Foulkes WD. BRCA1 and BRCA2: cancer treatment and outcomes. Familial Cancer . In press, 2006.





Classified as
Updated on ven, 2011-04-08 11:02
haut de page